1.80
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Hemispherx Biopharma Inc New | HEB | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.80 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.80 | USD |
Hemispherx Biopharma Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 4.40M | 2.44M | - | $ 367.00k | $ - | -9.86 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 120.65k | $ - | 0.00% | 876.73k | - |
Hemispherx Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HEB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Years | 25.08 | 28.60 | 1.69 | 9.43 | 1,050,807 | -23.28 | -92.82% |
| 5 Years | 37.9104 | 115.9488 | 1.69 | 26.29 | 745,906 | -36.11 | -95.25% |
Hemispherx Biopharma Description
| Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States. |
